Adjuvant immunotherapy shows no survival benefit for NSCLC patients achieving pCR after neoadjuvant treatment
Addition of immunotherapy continues to show survival benefit in prolonged follow-up in NRG Oncology trial for primary advanced stage or recurrent endometrial cancer - EurekAlert!
Proton therapy shows survival benefit in Phase III trial for patients with head and neck cancers - EurekAlert!
